Shionogi Announces Corporate Reorganization and Personnel Reassignment

Osaka, Japan, July 13, 2020 – Shionogi & Co., Ltd. (Head Office: Osaka; President and CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced today that it will implement the following corporate reorganization and personnel reassignments effective August 1, 2020.

1. Establishment of Ping An Shionogi Co., Ltd.

With the aim to realize one of the themes “Endeavor to offer new healthcare solutions based on data and AI utilization” as referred to in our Medium-term Business Plan “STS2030,” Shionogi will establish a joint venture in Shanghai, China, under a long-term partnership with Ping An Insurance (Group) Company of China Ltd. The purpose of the establishment is to provide healthcare solutions from the standpoint of society and patients as follows: (1) build a platform of data-driven research and development and conduct research on and development of pharmaceuticals (new drugs, generic drugs and non-prescription drugs) based on such a platform; (2) establish production and quality management systems based on AI technology and conduct quality assurance of pharmaceuticals (new drugs, generic drugs and non-prescription drugs) applying such technology; and (3) establish a sales and distribution platform using O2O (Online to Offline) and conduct the sale and distribution of pharmaceuticals (new drugs, generic drugs and non-prescription drugs).

 

1. Establishment of Ping An Shionogi (Hong Kong) Co., Ltd.

As with Ping An Shionogi Co., Ltd. under the long-term partnership with Ping An Insurance (Group) Company of China Ltd., a joint venture will be established in Hong Kong as the base for the purposes of mainly implementing capital investment, IP license management, and export and import of products to Asian countries.

 

1. Establishment of Shionogi (Hong Kong) Limited.

Under the long-term partnership with Ping An Insurance (Group) Company of China Ltd., the joint ventures mentioned in paragraphs I and II above will be established in Shanghai, China, and Hong Kong. A wholly owned subsidiary will be established separately in Hong Kong for the purposes of supervising these joint ventures and supporting their operations in China and other countries in Asia.

 

1. Reorganization of the Global Business Division

Towards the achievement of our global strategies indicated in STS2030, such as the provision of healthcare solutions from the standpoint of society and patients, the European and US Operations Department and the Global Business Department will be reorganized for the purpose of maximizing corporate value by accelerating and enhancing business support of the overseas Group companies.

 

1. Reorganization of the Government Affairs Department and the Quality Assurance Department

From the perspective of optimization of product life cycle management functions, the Regulatory Compliance Management Office will be dissolved positively to incorporate the CMC regulatory management function of the Regulatory Compliance Management Office into the Government Affairs Department, which will be called the “Regulatory Affairs Department.” Concurrently, the product assurance and compliance functions of the Regulatory Compliance Management Office will be incorporated into the Quality Assurance Department.